Seer (SEER) Change In Receivables : $1.03 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Seer Change In Receivables?

Seer's change in receivables for the quarter that ended in Mar. 2024 was $0.57 Mil. It means Seer's Accounts Receivable declined by $0.57 Mil from Dec. 2023 to Mar. 2024 .

Seer's change in receivables for the fiscal year that ended in Dec. 2023 was $0.30 Mil. It means Seer's Accounts Receivable declined by $0.30 Mil from Dec. 2022 to Dec. 2023 .

Seer's Accounts Receivable for the quarter that ended in Mar. 2024 was $3.82 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Seer's Days Sales Outstanding for the three months ended in Mar. 2024 was 114.89.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Seer's liquidation value for the three months ended in Mar. 2024 was $275.91 Mil.

Seer Change In Receivables Historical Data

The historical data trend for Seer's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seer Change In Receivables Chart

Seer Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.26

0.06

-3.88

-2.87

0.30

Seer Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-0.17	0.88	-1.45	1.03	0.57

Seer Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.03 Mil.

Seer (NAS:SEER) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Seer's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	3.815	/	3.03	*	91
=	114.89

2. In Ben Graham's calculation of liquidation value, Seer's accounts receivable are only considered to be worth 75% of book value:

Seer's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	308.55	-	38.407	+	0.75 * 3.815	+	0.5 * 5.809
=	275.91

Seer Change In Receivables Related Terms

Thank you for viewing the detailed overview of Seer's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Seer (SEER) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seer Inc (NAS:SEER) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

3800 Bridge Parkway, Suite 102, Redwood City, CA, USA, 94065

Website

https://www.seer.bio

Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access across the proteome.

Executives

Elona Esq. Kogan	officer: General Counsel and Secretary	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omid Farokhzad	director, 10 percent owner, officer: CEO and Chair of the Board	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Scott D Thomas	officer: Chief Commercial Officer	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
David R. Horn	officer: Chief Financial Officer	3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omead Ostadan	director, officer: President & COO	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Meeta Gulyani	director	C/O SEER, INC., 3800 BRIDGEPOINT PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Rachel E. Haurwitz	director	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Robert Langer	director	98 MONTVALE RD, NEWTON MA 02459
Maverick Ventures Investment Fund, L.p.	director	300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Capital Ventures, Llc	director	300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Advisors Fund, L.p.	director	300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
David Hallal	director	C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Terrance Mcguire	director	C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
David B Singer	director	C/O MAVERICK CAPITAL, LTD., 101 CALIFORNIA STREET, SUITE 4015, SAN FRANCISCO CA 94111
Cathy Friedman	director	C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005